Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bayer, spol. s r.o., slovensko - loratadín - 24 - antihistaminica, histamin

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

opella healthcare slovakia s.r.o., slovensko - paracetamol, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - ibuprofén, kombinácie - 07 - analgetica, antipyretica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reckitt benckiser (czech republic), spol. s r.o. , Česká republika - ibuprofén, kombinácie - 07 - analgetica, antipyretica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

hikma farmaceutica (portugal) s.a., portugalsko - sympatomimetiká - 52 - expectorantia, mucolytica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

hikma farmaceutica (portugal) s.a., portugalsko - expektoranciá - 52 - expectorantia, mucolytica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare limited - klopidogrel - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

adamed pharma s.a., poľsko - sulfametoxazol a trimetoprim - 42 - chemotherapeutica (vratane tuberkulostatik)

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ferring slovakia s.r.o., slovensko - budezonid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Uni Eropa - Slovak - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotické činidlá - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.